Language delay and developmental catch-up would be a clinical feature of pseudohypoparathyroidism type 1A during childhood.


Journal

Endocrine journal
ISSN: 1348-4540
Titre abrégé: Endocr J
Pays: Japan
ID NLM: 9313485

Informations de publication

Date de publication:
28 Mar 2019
Historique:
pubmed: 25 1 2019
medline: 28 7 2019
entrez: 25 1 2019
Statut: ppublish

Résumé

Pseudohypoparathyroidism type 1A (PHP1A) is characterized by resistance to multiple hormones, the Albright Hereditary Osteodystrophy phenotype, obesity, and developmental delay. Developmental delay usually appears prior to hypocalcemia due to parathyroid hormone resistance and could be a clinically important feature for early diagnosis of PHP1A. To date, however, the details have not been documented. With regard to developmental delays, we conducted a multicenter retrospective study of 22 PHP1A patients from 18 families who were diagnosed clinically or genetically from 2005 to 2015. For quantitative analysis of their development, we calculated the ratios of the milestone ages of the patients to those in normal reference data. The ratio of the ages with respect to speech development, i.e., speaking a first meaningful word (median: 1.67), was significantly higher than that for gross motor development, walking unassisted (median: 1.34). The ratio of age at stringing a two-word sentence (median: 1.32) was significantly lower than that of saying a first word (median: 1.84). Ten out of 11 (91%) patients exhibited two or three of the following clinical phenotypes: developmental delay, obesity, and hyperthyrotropinemia. These results suggest two possible clinical features of developmental delays in PHP1A patients: developmental delay is more obvious in speech acquisition than in gross motor skills, and speech delays could be attenuated during later childhood. Further, the presence of multiple of three clinical symptoms could be an important indicator to differentiate the diagnosis of PHP1A during early childhood.

Identifiants

pubmed: 30674755
doi: 10.1507/endocrj.EJ18-0326
doi:

Types de publication

Journal Article

Langues

eng

Pagination

215-221

Auteurs

Yuichi Miyakawa (Y)

Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo 113-8510, Japan.

Kei Takasawa (K)

Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo 113-8510, Japan.

Yohei Matsubara (Y)

Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo 113-8510, Japan.

Kenji Ihara (K)

Department of Pediatrics, Oita University Faculty of Medicine, Oita 879-5593, Japan.

Yoshiaki Ohtsu (Y)

Department of Pediatrics, Gunma University Graduate School of Medicine, Gunma 371-8511, Japan.

Hotaka Kamasaki (H)

Department of Pediatrics, Sapporo Medical University School of Medicine, Hokkaido 060-8543, Japan.

Kazuteru Kitsuda (K)

Department of Pediatrics, Kitasato University, Kanagawa 252-0375, Japan.

Hironori Kobayashi (H)

Department of Pediatrics, Shimane University Faculty of Medicine, Shimane 690-8501, Japan.

Mari Satoh (M)

Department of Pediatrics, Toho University Omori Medical Center, Tokyo 143-8541, Japan.

Sinichiro Sano (S)

Department of Pediatrics, Hamamatsu University School of Medicine, Shizuoka 431-3192, Japan.

Sumito Dateki (S)

Department of Pediatrics, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8501, Japan.

Hiroshi Mochizuki (H)

Division of Endocrinology and Metabolism, Saitama Children's Medical Center, Saitama 330-8777, Japan.

Ichiro Yokota (I)

Division of Pediatric Endocrinology and Metabolism, Shikoku Medical Center for Children and Adults, Kagawa 765-8507, Japan.

Yukihiro Hasegawa (Y)

Division of Endocrinology and Metabolism, Tokyo Metropolitan Children's Medical Center, Tokyo 183-8561, Japan.

Kenichi Kashimada (K)

Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo 113-8510, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH